136 related articles for article (PubMed ID: 7497523)
1. Suppression of immunopathology in schistosomiasis by interleukin-2-targeted fusion toxin, DAB389IL-2. I. Studies of in vitro and in vivo efficacy.
Ramadan MA; Gabr NS; Bacha P; Günzler V; Phillips SM
Cell Immunol; 1995 Dec; 166(2):217-26. PubMed ID: 7497523
[TBL] [Abstract][Full Text] [Related]
2. Modulation of T lymphocyte proliferation in mice infected with Schistosoma mansoni: VIP suppresses mitogen- and antigen-induced T cell proliferation possibly by inhibiting IL-2 production.
Metwali A; Blum A; Mathew R; Sandor M; Lynch RG; Weinstock JV
Cell Immunol; 1993 Jun; 149(1):11-23. PubMed ID: 8099848
[TBL] [Abstract][Full Text] [Related]
3. Effect of DAB(389)IL-2 immunotoxin on the course of experimental autoimmune encephalomyelitis in Lewis rats.
Phillips SM; Bhopale MK; Constantinescu CS; Ciric B; Hilliard B; Ventura E; Lavi E; Rostami A
J Neurol Sci; 2007 Dec; 263(1-2):59-69. PubMed ID: 17603081
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies.
Nichols J; Foss F; Kuzel TM; LeMaistre CF; Platanias L; Ratain MJ; Rook A; Saleh M; Schwartz G
Eur J Cancer; 1997 Jan; 33 Suppl 1():S34-6. PubMed ID: 9166099
[TBL] [Abstract][Full Text] [Related]
5. Vasoactive intestinal peptide stimulates T lymphocytes to release IL-5 in murine schistosomiasis mansoni infection.
Mathew RC; Cook GA; Blum AM; Metwali A; Felman R; Weinstock JV
J Immunol; 1992 Jun; 148(11):3572-7. PubMed ID: 1588046
[TBL] [Abstract][Full Text] [Related]
6. Lack of antigen-specific Th1 response alters granuloma formation and composition in Schistosoma mansoni-infected MyD88-/- mice.
Layland LE; Wagner H; da Costa CU
Eur J Immunol; 2005 Nov; 35(11):3248-57. PubMed ID: 16276483
[TBL] [Abstract][Full Text] [Related]
7. Characterization of regulatory (interferon-alpha/beta) and accessory (LAF/IL 1) monokine activities from liver granuloma macrophages of Schistosoma mansoni-infected mice.
Elliott DE; Righthand VF; Boros DL
J Immunol; 1987 Apr; 138(8):2653-62. PubMed ID: 3104471
[TBL] [Abstract][Full Text] [Related]
8. Schistosome-infected IL-4 receptor knockout (KO) mice, in contrast to IL-4 KO mice, fail to develop granulomatous pathology while maintaining the same lymphokine expression profile.
Jankovic D; Kullberg MC; Noben-Trauth N; Caspar P; Ward JM; Cheever AW; Paul WE; Sher A
J Immunol; 1999 Jul; 163(1):337-42. PubMed ID: 10384133
[TBL] [Abstract][Full Text] [Related]
9. An IL-2-toxin, DAB389IL-2, inhibits delayed-type hypersensitivity but enhances IgE antibody production.
Pullerits T; Lundin S; Dahlgren U; Telemo E; Hanson LA; Lötvall J
J Allergy Clin Immunol; 1999 May; 103(5 Pt 1):843-9. PubMed ID: 10329818
[TBL] [Abstract][Full Text] [Related]
10. Nasal administration of Schistosoma mansoni egg antigens-cholera toxin B subunit conjugate to infected mice reduces immunopathology and mortality.
Sun JB; Li BL; Lakew M; Grzych JM; Capron A; Czerkinsky C; Holmgren J
Adv Exp Med Biol; 2001; 495():305-9. PubMed ID: 11774583
[No Abstract] [Full Text] [Related]
11. Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice.
Sun JB; Mielcarek N; Lakew M; Grzych JM; Capron A; Holmgren J; Czerkinsky C
J Immunol; 1999 Jul; 163(2):1045-52. PubMed ID: 10395703
[TBL] [Abstract][Full Text] [Related]
12. Retroviral Foxp3 gene transfer ameliorates liver granuloma pathology in Schistosoma mansoni infected mice.
Singh KP; Gerard HC; Hudson AP; Reddy TR; Boros DL
Immunology; 2005 Mar; 114(3):410-7. PubMed ID: 15720442
[TBL] [Abstract][Full Text] [Related]
13. Changing patterns of lymphocyte proliferation, IL-2 production and utilization, and IL-2 receptor expression in mice infected with Schistosoma mansoni.
Yamashita T; Boros DL
J Immunol; 1990 Jul; 145(2):724-31. PubMed ID: 1973188
[TBL] [Abstract][Full Text] [Related]
14. Regulation of granulomatous inflammation in murine schistosomiasis. V. Antigen-induced T cell-derived suppressor factors down-regulate proliferation and IL-2, but not IL-4, production by CD4+ effector T cells.
Fidel PL; Boros DL
J Immunol; 1991 Mar; 146(6):1941-8. PubMed ID: 1672335
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes.
Bousvaros A; Stevens AC; Strom TB; Murphy J; Lamont JT
Dig Dis Sci; 1997 Jul; 42(7):1542-8. PubMed ID: 9246061
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
Saleh MN; LeMaistre CF; Kuzel TM; Foss F; Platanias LC; Schwartz G; Ratain M; Rook A; Freytes CO; Craig F; Reuben J; Sams MW; Nichols JC
J Am Acad Dermatol; 1998 Jul; 39(1):63-73. PubMed ID: 9674399
[TBL] [Abstract][Full Text] [Related]
17. IL-10 is crucial for the transition from acute to chronic disease state during infection of mice with Schistosoma mansoni.
Sadler CH; Rutitzky LI; Stadecker MJ; Wilson RA
Eur J Immunol; 2003 Apr; 33(4):880-8. PubMed ID: 12672053
[TBL] [Abstract][Full Text] [Related]
18. IL-2 contributes to the IL-5 response in granulomas from mice infected with Schistosoma mansoni.
Metwali A; Elliott D; Mathew R; Blum A; Weinstock JV
J Immunol; 1993 Jan; 150(2):536-42. PubMed ID: 8419486
[TBL] [Abstract][Full Text] [Related]
19. Recombinant IL-10 and IL-10/Fc treatment down-regulate egg antigen-specific delayed hypersensitivity reactions and egg granuloma formation in schistosomiasis.
Flores-Villanueva PO; Zheng XX; Strom TB; Stadecker MJ
J Immunol; 1996 May; 156(9):3315-20. PubMed ID: 8617955
[TBL] [Abstract][Full Text] [Related]
20. DAB
Bhopale MK; Hilliard B; Constantinescu CS; Phillips SM; Rostami A
Immunopharmacol Immunotoxicol; 2017 Dec; 39(6):318-329. PubMed ID: 28929835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
